J. Didkowska, U. Wojciechowska, M. Ma?czuk, and J. ?obaszewski, Lung cancer epidemiology: Contemporary and future challenges worldwide, Ann. Transl. Med, 2016.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer Statistics, CA Cancer J. Clin, vol.67, pp.7-30, 2017.

L. A. Torre, F. Islami, R. L. Siegel, E. M. Ward, and A. Jemal, Global Cancer in Women: Burden and Trends, Cancer Epidemiol. Biomark. Prev, vol.26, pp.444-457, 2017.

S. Devarakonda, A. Masood, and R. Govindan, Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions, Hematol. Oncol. Clin. North Am, vol.31, pp.1-12, 2017.

F. Oberndorfer and L. Müllauer, Molecular pathology of lung cancer: Current status and perspectives, Curr. Opin. Oncol, vol.30, pp.69-76, 2018.

S. Schallenberg, S. Merkelbach-bruse, and R. Buettner, Lung cancer as a paradigm for precision oncology in solid tumours, Virchows Arch, vol.471, pp.221-233, 2017.

Y. Khagi, R. Kurzrock, and S. P. Patel, Next generation predictive biomarkers for immune checkpoint inhibition, Cancer Metastasis Rev, vol.36, pp.179-190, 2017.

C. Mascaux, M. Tsao, and F. R. Hirsch, Genomic Testing in Lung Cancer: Past, Present, and Future, J. Natl. Compr. Cancer Netw, vol.16, pp.323-334, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02143584

N. Akhtar and J. G. Bansal, Risk factors of Lung Cancer in nonsmoker, Curr. Probl. Cancer, vol.41, pp.328-339, 2017.

S. De-matteis, D. Heederik, A. Burdorf, C. Colosio, P. Cullinan et al., European Respiratory Society Environment and Health Committee Current and new challenges in occupational lung diseases, Eur. Respir. Rev, vol.26, 2017.

R. E. Hewitt, Biobanking: The foundation of personalized medicine, Curr. Opin. Oncol, vol.23, pp.112-119, 2011.

K. Zatloukal and P. Hainaut, Human tissue biobanks as instruments for drug discovery and development: Impact on personalized medicine, Biomark. Med, vol.4, pp.895-903, 2010.

M. Plebani, The detection and prevention of errors in laboratory medicine, Ann. Clin. Biochem, vol.47, pp.101-110, 2010.

L. P. Freedman, I. M. Cockburn, and T. S. Simcoe, The Economics of Reproducibility in Preclinical Research, PLoS Biol, vol.13, 2015.

G. Botti, R. Franco, M. Cantile, G. Ciliberto, and P. A. Ascierto, Tumor biobanks in translational medicine, J. Transl. Med, vol.10, 2012.

G. Botti, R. De-cecio, and M. Cantile, Tumor biobank as fundamental bio-resource for RNA analysis technologies, vol.29, pp.106-107, 2017.

L. Braun, M. Lesperance, A. Mes-massons, M. S. Tsao, and P. H. Watson, Individual Investigator Profiles of Biospecimen Use in Cancer Research, Biopreserv. Biobank, vol.12, pp.192-198, 2014.

K. Washetine, E. Long, V. Hofman, S. Lassalle, M. Ilie et al., The accreditation of a surgical pathology and somatic genetic laboratory (LPCE, CHU of Nice) according to the ISO 15189 norm: Sharing of experience, Ann. Pathol, vol.33, pp.386-397, 2013.

A. Carter and F. Betsou, Quality assurance in cancer biobanking, Biopreserv. Biobank, vol.9, pp.157-163, 2011.

P. Hofman, Liquid biopsy and therapeutic targets: Present and future issues in thoracic oncology, Cancers, vol.9, 2017.

P. Hofman, Liquid biopsy for early detection of lung cancer, Curr. Opin. Oncol, vol.29, pp.73-78, 2017.

M. Ilie, V. Hofman, E. Long, O. Bordone, E. Selva et al., Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?, Ann. Transl. Med, 2014.

C. Rolfo, P. C. Mack, G. V. Scagliotti, P. Baas, F. Barlesi et al., IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC), J. Thorac. Oncol, 2018.

M. C. Brahimi-horn, D. Ben-hail, M. Ilie, P. Gounon, M. Rouleau et al., Expression of a truncated active form of VDAC1 in lung cancer associates with hypoxic cell survival and correlates with progression to chemotherapy resistance, Cancer Res, vol.72, pp.2140-2150, 2012.

R. Fouret, J. Laffaire, P. Hofman, M. Beau-faller, J. Mazieres et al., A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma, Clin. Cancer Res, vol.18, pp.5606-5616, 2012.

A. Italiano, A. B. Cortot, M. Ilie, G. Martel-planche, T. Fabas et al., EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti-EGFR treatment of a rare lung malignancy, Int. J. Cancer, vol.125, pp.2479-2482, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00435717

B. Job, A. Bernheim, M. Beau-faller, S. Camilleri-broët, P. Girard et al., LG Investigators Genomic aberrations in lung adenocarcinoma in never smokers, PLoS ONE, vol.5, 2010.

V. Hofman, M. I. Ilie, E. Long, E. Selva, C. Bonnetaud et al., Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: Comparison of the efficacy of the CellSearch Assay ? and the isolation by size of epithelial tumor cell method, Int. J. Cancer, vol.129, pp.1651-1660, 2011.

P. Hofman, M. Ilie, V. Hofman, S. Roux, A. Valent et al., Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma, Ann. Oncol, vol.23, pp.1738-1743, 2012.

M. I. Ilie, V. Hofman, C. Bonnetaud, K. Havet, V. Lespinet-fabre et al., Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma, Virchows Arch, vol.457, pp.483-495, 2010.

M. Ilie, N. M. Mazure, V. Hofman, R. E. Ammadi, C. Ortholan et al., High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer, Br. J. Cancer, vol.102, pp.1627-1635, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00497438

M. Ilie, S. Khambata-ford, C. Copie-bergman, L. Huang, J. Juco et al., Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms, PLoS ONE, vol.12, 2017.

M. Ilie, J. Juco, L. Huang, V. Hofman, S. Khambata-ford et al., Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients, Cancer Cytopathol, vol.126, pp.264-274, 2018.

M. Ilie, E. Szafer-glusman, V. Hofman, E. Long-mira, R. Suttmann et al., Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients, Oncotarget, vol.8, pp.26112-26121, 2017.

J. Mazières, I. Rouquette, B. Lepage, J. Milia, L. Brouchet et al., Specificities of Lung Adenocarcinoma in Women Who Have Never Smoked, J. Thorac. Oncol, vol.8, pp.923-929, 2013.

M. I. Ilie, V. Hofman, C. Ortholan, R. Ammadi, C. El;-bonnetaud et al., Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis, Int. J. Cancer, vol.128, pp.1614-1623, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00497435

M. Puisségur, N. M. Mazure, T. Bertero, L. Pradelli, S. Grosso et al., miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity, Cell Death Differ, vol.18, pp.465-478, 2011.

E. Rakha, M. J. Pajares, M. Ilie, R. Pio, J. Echeveste et al., Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators, Eur. J. Cancer, vol.51, pp.1897-1903, 2015.

C. Sanfiorenzo, M. I. Ilie, A. Belaid, F. Barlési, J. Mouroux et al., Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC, PLoS ONE, vol.8, 2013.

M. Ilie, E. Long, C. Butori, V. Hofman, C. Coelle et al., ALK-gene rearrangement: A comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma, Ann. Oncol, vol.23, pp.2907-2913, 2012.

M. Ilie, V. Hofman, C. Ortholan, C. Bonnetaud, C. Coëlle et al., Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer, Cancer, vol.118, pp.1726-1737, 2012.

M. Ilie, V. Hofman, J. Zangari, J. Chiche, J. Mouroux et al., Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients, Lung Cancer, vol.82, pp.16-23, 2013.

M. Ilie, E. Long, V. Hofman, B. Dadone, C. H. Marquette et al., Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients, Ann. Oncol, vol.24, pp.742-748, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01701142

M. Ilie, M. Nunes, L. Blot, V. Hofman, E. Long-mira et al., Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps, Cancer Med, vol.4, pp.201-211, 2015.

M. Ilié, E. Szafer-glusman, V. Hofman, E. Chamorey, S. Lalvée et al., Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer, Ann. Oncol, vol.29, pp.193-199, 2018.

M. Ilie, E. Long, V. Hofman, E. Selva, C. Bonnetaud et al., Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer, Br. J. Cancer, vol.110, pp.1236-1243, 2014.

C. Chabannon, A. Honstettre, L. Daufresne, P. Martin, C. Bonnetaud et al., Publication of biological samples collections catalogues by tumor banks, Bull. Cancer, vol.97, pp.181-189, 2010.

L. Chalabreysse, V. Thomas-de-montpreville, A. De-muret, V. Hofman, S. Lantuejoul et al., Rythmic-pathology: The French national pathology network for thymic epithelial tumours, Ann. Pathol, vol.34, pp.87-91, 2014.

M. Doucet, K. F. Becker, J. Björkman, J. Bonnet, B. Clément et al., Quality Matters: 2016 Annual Conference of the National Infrastructures for Biobanking, vol.15, pp.270-276, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01744441

F. Galateau-sallé, A. Gilg-soit-ilg, N. Le-stang, P. Brochard, J. C. Pairon et al., The French mesothelioma network from, Ann. Pathol, vol.34, pp.51-63, 1998.

, Biopreserv. Biobank, vol.9, pp.5-6, 2011.

E. Gormally, I. Hardy, E. Caboux, J. Di-donato, P. Hainaut et al., Training the Next Generation of Biobankers: A Two-Year Master's Course in the Management of Biobanks, Biopreserv. Biobank, vol.15, pp.438-450, 2017.

C. H. Lagardere, French Biobank Secures Specimens, p.17, 2018.

, Les missions d'enseignement, de recherche, de référence et d'innovation-MERRI, p.15, 2018.

K. Washetine, M. Kara-borni, S. Heeke, C. Bonnetaud, F. Jean-marc et al., Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA, Cancers, vol.10, 0195.
URL : https://hal.archives-ouvertes.fr/hal-01835099

G. Bevilacqua, F. Bosman, T. Dassesse, H. Höfler, A. Janin et al., The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch, vol.456, pp.449-454, 2010.

P. Hofman, C. Bréchot, K. Zatloukal, G. Dagher, and B. Clément, Public-private relationships in biobanking: A still underestimated key component of open innovation, Virchows Arch, vol.464, pp.3-9, 2014.

R. Hewitt and P. Hainaut, Biobanking in a Fast Moving World: An International Perspective, JNCI Monogr, pp.50-51, 2011.

J. Vaught and N. C. Lockhart, The evolution of biobanking best practices, Clin. Chim. Acta, vol.413, pp.1569-1575, 2012.

T. Castillo-pelayo, S. Babinszky, J. Leblanc, and P. H. Watson, The Importance of Biobanking in Cancer Research, Biopreserv. Biobank, vol.13, pp.172-177, 2015.

A. Cole, S. Cheah, S. Dee, S. Hughes, P. H. Watson et al., Use Correlates with Emerging Techniques in Cancer Research: Impact on Planning Future Biobanks, Biopreserv. Biobank, vol.10, pp.518-525, 2012.

S. E. Hughes, R. O. Barnes, and P. H. Watson, Biospecimen use in cancer research over two decades, Biopreserv. Biobank, vol.8, pp.89-97, 2010.

B. Clément, M. Yuille, K. Zaltoukal, H. Wichmann, G. Anton et al., Expert Group on cost recovery in biobanks Public biobanks: Calculation and recovery of costs, Sci. Transl. Med, vol.6, 2014.

M. B. Gonzalez-sanchez, E. Lopez-valeiras, M. M. Morente, and O. Fernández-lago, Cost Model for Biobanks. Biopreserv. Biobank, vol.11, pp.272-277, 2013.

A. Cambon-thomsen, G. A. Thorisson, L. Mabile, and . Workshop, Group The role of a bioresource research impact factor as an incentive to share human bioresources, Nat. Genet, vol.43, pp.503-504, 2011.

L. Mabile, R. Dalgleish, G. A. Thorisson, M. Deschênes, R. Hewitt et al., Quantifying the use of bioresources for promoting their sharing in scientific research, Gigascience, vol.2, issue.7, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00823375

V. Hofman, C. Bonnetaud, M. C. Gaziello, M. Ilie, S. Lassalle et al., The Nice CHU biobank experience to collect patients' informed consent for research context, Ann. Pathol, vol.30, p.22, 2004.

V. Hofman, M. Ilie, E. Long, K. Washetine, C. Chabannon et al., Measuring the contribution of tumor biobanks to research in oncology: Surrogate indicators and bibliographic output, Biopreserv. Biobank, vol.11, pp.235-244, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-01978789

W. H. Yong, S. M. Dry, and M. Shabihkhani, A practical approach to clinical and research biobanking, Methods Mol. Biol, vol.1180, pp.137-162, 2014.

C. Ellervik and J. Vaught, Preanalytical variables affecting the integrity of human biospecimens in biobanking, Clin. Chem, vol.61, pp.914-934, 2015.

A. Hubel, R. Spindler, and A. P. Skubitz, Storage of human biospecimens: Selection of the optimal storage temperature, Biopreserv. Biobank, vol.12, pp.165-175, 2014.

Y. Ma, H. Dai, and X. Kong, Impact of warm ischemia on gene expression analysis in surgically removed biosamples, Anal. Biochem, vol.423, pp.229-235, 2012.

M. Basik, A. Aguilar-mahecha, C. Rousseau, Z. Diaz, S. Tejpar et al., Biopsies: Next-generation biospecimens for tailoring therapy, Nat. Rev. Clin. Oncol, vol.10, pp.437-450, 2013.

Z. Diaz, A. Aguilar-mahecha, E. R. Paquet, M. Basik, M. Orain et al., Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine, Mod. Pathol, vol.26, pp.1413-1424, 2013.

J. Luo, X. Guo, X. Tang, X. Sun, Z. Yang et al., Intravital biobank and personalized cancer therapy: The correlation with omics, Int. J. Cancer, vol.135, pp.1511-1516, 2014.

B. Wei and R. M. Simpson, Digital pathology and image analysis augment biospecimen annotation and biobank quality assurance harmonization, Clin. Biochem, vol.47, pp.274-279, 2014.